Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study

Biliary tract cancer (BTC) has been inconsistently identified according to its location in epidemiological and clinical studies. This study retrospectively reviewed the treatment pattern and prognosis of BTC according to tumor location using the Korea Central Cancer Registry data of 97,676 patients with BTC from 2006 to 2017. The proportion of localized and regional Surveillance, Epidemiology, and End Results (SEER) stage was the highest in ampulla of Vater (AoV, 78.2%) cancer, followed by extrahepatic bile duct (BD, 68.3%), gallbladder (GB, 52.6%), and intrahepatic BD (49.5%) cancers. Overall, the no active anti-cancer treatment rate was the highest in intrahepatic BD (52.8%), followed by extrahepatic BD (49.5%), GB (39.6%), and AoV cancers (28.9%). The 5-year relative survival rate was the highest in AoV (48.5%), followed by GB (28.5%), extrahepatic BD (19.9%), and intrahepatic BD (10.8%) cancers, which significantly improved over time, except for intrahepatic BD cancer. In the localized and regional stage, older patients had a higher risk of receiving no active anti-cancer treatment in each tumor location after adjusting for period and sex. BTC statistics should be reported separately according to tumor location due to its distinct SEER stage distribution, treatment pattern, and prognosis. Care should be taken in elderly patients to reduce the rate of no active anti-cancer treatment.

Automated summary

This study retrospectively reviewed the treatment pattern and prognosis of biliary tract cancer (BTC) according to tumor location. The results showed that tumor location has an impact on treatment pattern and prognosis. Vater's ampulla cancer was the most common tumor location for BTC patients, followed by extrahepatic bile duct cancer, gallbladder cancer, and intrahepatic bile duct cancer. The highest rate of no active anti-cancer treatment was found in intrahepatic bile duct cancer, while the highest 5-year relative survival rate was found in Vater's ampulla cancer. Older patients had a higher risk of receiving no active anti-cancer treatment in each tumor location.